Sie befinden Sich nicht im Netzwerk der Universität Paderborn. Der Zugriff auf elektronische Ressourcen ist gegebenenfalls nur via VPN oder Shibboleth (DFN-AAI) möglich. mehr Informationen...
Ergebnis 3 von 9
Cell, 2018-04, Vol.173 (2), p.371-385.e18
2018

Details

Autor(en) / Beteiligte
Titel
Comprehensive Characterization of Cancer Driver Genes and Mutations
Ist Teil von
  • Cell, 2018-04, Vol.173 (2), p.371-385.e18
Ort / Verlag
United States: Elsevier Inc
Erscheinungsjahr
2018
Link zum Volltext
Quelle
EZB Electronic Journals Library
Beschreibungen/Notizen
  • Identifying molecular cancer drivers is critical for precision oncology. Multiple advanced algorithms to identify drivers now exist, but systematic attempts to combine and optimize them on large datasets are few. We report a PanCancer and PanSoftware analysis spanning 9,423 tumor exomes (comprising all 33 of The Cancer Genome Atlas projects) and using 26 computational tools to catalog driver genes and mutations. We identify 299 driver genes with implications regarding their anatomical sites and cancer/cell types. Sequence- and structure-based analyses identified >3,400 putative missense driver mutations supported by multiple lines of evidence. Experimental validation confirmed 60%–85% of predicted mutations as likely drivers. We found that >300 MSI tumors are associated with high PD-1/PD-L1, and 57% of tumors analyzed harbor putative clinically actionable events. Our study represents the most comprehensive discovery of cancer genes and mutations to date and will serve as a blueprint for future biological and clinical endeavors. [Display omitted] •PanSoftware applied to PanCancer data identified 299 cancer driver genes•Driver genes and mutations are shared across anatomical origins and cell types•In silico discovery of ∼3,400 driver mutations coupled with experimental validation•57% of tumors harbor potentially actionable oncogenic events A comprehensive analysis of oncogenic driver genes and mutations in >9,000 tumors across 33 cancer types highlights the prevalence of clinically actionable cancer driver events in TCGA tumor samples.

Weiterführende Literatur

Empfehlungen zum selben Thema automatisch vorgeschlagen von bX